A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Tongji Hospital
Canadian Cancer Trials Group
J-Pharma Co., Ltd.
Centre Leon Berard
Peking University
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
Hoffmann-La Roche
Bristol-Myers Squibb
M.D. Anderson Cancer Center
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Centre Oscar Lambret
AstraZeneca
Medical College of Wisconsin
Incyte Corporation
University of California, Irvine
Sun Yat-sen University
MedImmune LLC
Northwell Health
M.D. Anderson Cancer Center
Hoffmann-La Roche
Institut du Cancer de Montpellier - Val d'Aurelle
University of Campania Luigi Vanvitelli
Jiangsu HengRui Medicine Co., Ltd.
GlaxoSmithKline
Sun Yat-sen University
UNICANCER
Cardiff Oncology
Peking University Cancer Hospital & Institute
Shanghai Zhongshan Hospital
Peking University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UNICANCER
Maimónides Biomedical Research Institute of Córdoba
UNICANCER
UNICANCER
Massachusetts General Hospital
Mirror Biologics, Inc.
Grupo Espanol Multidisciplinario del Cancer Digestivo
Sun Yat-sen University
GERCOR - Multidisciplinary Oncology Cooperative Group
ITM Solucin GmbH
NovaOnco Therapeutics Co., Ltd.
Weill Medical College of Cornell University
Shanghai Pudong Hospital
Leap Therapeutics, Inc.
Zhejiang Cancer Hospital